AR007004A1 - Sal de dihidrato de mesilato de 5-(2-(4-(1,2-benzoisotiazol-3-il)-1- piperazinil)etil)-6-cloro-1,3-dihidro-2h-indol-2-ona y composicionesfarmaceuticas que la contienen - Google Patents

Sal de dihidrato de mesilato de 5-(2-(4-(1,2-benzoisotiazol-3-il)-1- piperazinil)etil)-6-cloro-1,3-dihidro-2h-indol-2-ona y composicionesfarmaceuticas que la contienen

Info

Publication number
AR007004A1
AR007004A1 ARP970101856A ARP970101856A AR007004A1 AR 007004 A1 AR007004 A1 AR 007004A1 AR P970101856 A ARP970101856 A AR P970101856A AR P970101856 A ARP970101856 A AR P970101856A AR 007004 A1 AR007004 A1 AR 007004A1
Authority
AR
Argentina
Prior art keywords
piperazinyl
dihydro
ethyl
pharmaceutical compositions
benzoisotiazol
Prior art date
Application number
ARP970101856A
Other languages
English (en)
Spanish (es)
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of AR007004A1 publication Critical patent/AR007004A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Saccharide Compounds (AREA)
ARP970101856A 1996-05-07 1997-05-05 Sal de dihidrato de mesilato de 5-(2-(4-(1,2-benzoisotiazol-3-il)-1- piperazinil)etil)-6-cloro-1,3-dihidro-2h-indol-2-ona y composicionesfarmaceuticas que la contienen AR007004A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US1675796P 1996-05-07 1996-05-07

Publications (1)

Publication Number Publication Date
AR007004A1 true AR007004A1 (es) 1999-10-13

Family

ID=21778804

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP970101856A AR007004A1 (es) 1996-05-07 1997-05-05 Sal de dihidrato de mesilato de 5-(2-(4-(1,2-benzoisotiazol-3-il)-1- piperazinil)etil)-6-cloro-1,3-dihidro-2h-indol-2-ona y composicionesfarmaceuticas que la contienen

Country Status (40)

Country Link
US (1) US6245765B1 (cg-RX-API-DMAC7.html)
EP (1) EP0918772B1 (cg-RX-API-DMAC7.html)
JP (1) JP3494659B2 (cg-RX-API-DMAC7.html)
KR (1) KR100333215B1 (cg-RX-API-DMAC7.html)
CN (1) CN1091769C (cg-RX-API-DMAC7.html)
AP (1) AP765A (cg-RX-API-DMAC7.html)
AR (1) AR007004A1 (cg-RX-API-DMAC7.html)
AT (1) ATE278689T1 (cg-RX-API-DMAC7.html)
AU (1) AU731267B2 (cg-RX-API-DMAC7.html)
BG (1) BG63544B1 (cg-RX-API-DMAC7.html)
BR (1) BR9709889A (cg-RX-API-DMAC7.html)
CA (1) CA2252898C (cg-RX-API-DMAC7.html)
CO (1) CO4940466A1 (cg-RX-API-DMAC7.html)
CZ (1) CZ289215B6 (cg-RX-API-DMAC7.html)
DE (1) DE69731094T2 (cg-RX-API-DMAC7.html)
DK (1) DK0918772T3 (cg-RX-API-DMAC7.html)
DZ (1) DZ2222A1 (cg-RX-API-DMAC7.html)
EA (1) EA001190B1 (cg-RX-API-DMAC7.html)
EG (1) EG24076A (cg-RX-API-DMAC7.html)
ES (1) ES2229342T3 (cg-RX-API-DMAC7.html)
GT (1) GT199700052A (cg-RX-API-DMAC7.html)
HR (1) HRP970236B1 (cg-RX-API-DMAC7.html)
ID (1) ID16867A (cg-RX-API-DMAC7.html)
IL (1) IL126591A (cg-RX-API-DMAC7.html)
IS (1) IS2080B (cg-RX-API-DMAC7.html)
MA (1) MA24171A1 (cg-RX-API-DMAC7.html)
MY (1) MY119997A (cg-RX-API-DMAC7.html)
NO (1) NO312514B1 (cg-RX-API-DMAC7.html)
NZ (1) NZ332218A (cg-RX-API-DMAC7.html)
OA (1) OA10909A (cg-RX-API-DMAC7.html)
PL (1) PL188330B1 (cg-RX-API-DMAC7.html)
PT (1) PT918772E (cg-RX-API-DMAC7.html)
SI (1) SI0918772T1 (cg-RX-API-DMAC7.html)
SK (1) SK282837B6 (cg-RX-API-DMAC7.html)
TN (1) TNSN97074A1 (cg-RX-API-DMAC7.html)
TR (1) TR199802240T2 (cg-RX-API-DMAC7.html)
TW (1) TW491847B (cg-RX-API-DMAC7.html)
UA (1) UA46840C2 (cg-RX-API-DMAC7.html)
WO (1) WO1997042191A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA973876B (cg-RX-API-DMAC7.html)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HN1996000101A (es) * 1996-02-28 1997-06-26 Inc Pfizer Terapia combinada para la osteoporosis
UA57734C2 (uk) 1996-05-07 2003-07-15 Пфайзер Інк. Комплекси включення арилгетероциклічних солей
IL127497A (en) * 1997-12-18 2002-07-25 Pfizer Prod Inc Medicinal products containing piperazinyl-heterocyclic compounds for the treatment of psychiatric disorders
US20080113025A1 (en) * 1998-11-02 2008-05-15 Elan Pharma International Limited Compositions comprising nanoparticulate naproxen and controlled release hydrocodone
NZ551012A (en) * 2000-06-02 2008-04-30 Pfizer Prod Inc Use of S-methyl-dihydro-ziprasidone administered via either the oral, parenteral (such as subcutaneous, intravenous, intramuscular, intrasternal and infusion techniques), rectal, intranasal or topical routes in doses ranging from 0.5 to 500 mg per day
UY27668A1 (es) 2002-02-20 2003-10-31 Pfizer Prod Inc Composición de ziprasidona y controles sintéticos
US20040048876A1 (en) * 2002-02-20 2004-03-11 Pfizer Inc. Ziprasidone composition and synthetic controls
AU2004237951A1 (en) 2003-05-16 2004-11-25 Pfizer Products Inc. Therapeutic combinations of atypical antipsychotics with GABA modulators, anticonvulsants or benzodiazapines
EP1530570A2 (en) * 2003-06-03 2005-05-18 Teva Pharmaceutical Industries Limited CRISTALLINE ZIPRASIDONE HCl AND PROCESSES FOR PREPARATION THEREOF
EP1628973A2 (en) 2003-10-24 2006-03-01 Teva Pharmaceutical Industries Ltd. Processes for preparation of ziprasidone
BRPI0510942A (pt) * 2004-05-11 2007-07-17 Pfizer Prod Inc combinação de antipsicóticos atìpicos e antagonistas do receptor 5-ht1b
CA2467538C (en) 2004-05-14 2010-08-24 Apotex Pharmachem Inc. New amorphous ziprasidone hydrochloride (5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-2h-indol-2-one hydrochloride) and processes to produce the same
CA2471219A1 (en) 2004-06-14 2005-12-14 Apotex Pharmachem Inc. Improved preparation of an anhydrate form of 5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-2h-indol-2-one hydrochloride (ziprasidone hydrochloride)
US7777037B2 (en) * 2004-10-27 2010-08-17 Dr. Reddy's Laboratories Limited Ziprasidone process
CA2587710C (en) * 2004-11-16 2014-10-21 Elan Pharma International Ltd. Injectable nanoparticulate olanzapine formulations
CA2591670A1 (en) * 2005-02-11 2006-08-17 Teva Pharmaceutical Industries Ltd. Process of preparing ziprasidone mesylate
WO2006086779A1 (en) * 2005-02-11 2006-08-17 Teva Pharmaceutical Industries Ltd. Amorphous ziprasidone mesylate
US20080254114A1 (en) * 2005-03-03 2008-10-16 Elan Corporation Plc Controlled Release Compositions Comprising Heterocyclic Amide Derivative Nanoparticles
ITMI20050346A1 (it) 2005-03-07 2006-09-08 Dipharma Spa Forma solida di ziprasidone cloridrato
CA2500667C (en) 2005-03-11 2013-01-15 Apotex Pharmachem Inc. Preparation of acid addition salts of ziprasidone and intermediates thereof by solid phase-gas phase reactions
WO2006098834A2 (en) * 2005-03-14 2006-09-21 Teva Pharmaceutical Industries Ltd. Crystalline forms of ziprasidone mesylate
WO2006099452A1 (en) * 2005-03-14 2006-09-21 Teva Pharmaceutical Industries Ltd. Anhydrous ziprasidone mesylate and a process for its preparation
ITMI20052216A1 (it) * 2005-11-18 2007-05-19 Dipharma Spa Procedimento per la preparazione di ziprasidone
WO2008143960A1 (en) * 2007-05-18 2008-11-27 Scidose Llc Ziprasidone formulations
WO2009156889A1 (en) * 2008-06-25 2009-12-30 Pfizer Inc. Diaryl compounds and uses thereof
JP5893616B2 (ja) * 2010-10-18 2016-03-23 大日本住友製薬株式会社 注射用徐放性製剤
SI23610A (sl) 2011-01-13 2012-07-31 Diagen@d@o@o Nove adicijske soli ziprasidona postopek za njihovo pripravo in njihova uporaba v terapiji
US20140206667A1 (en) 2012-11-14 2014-07-24 Michela Gallagher Methods and compositions for treating schizophrenia

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX173362B (es) * 1987-03-02 1994-02-23 Pfizer Compuestos de piperazinil heterociclicos y procedimiento para su preparacion
US4831031A (en) * 1988-01-22 1989-05-16 Pfizer Inc. Aryl piperazinyl-(C2 or C4) alkylene heterocyclic compounds having neuroleptic activity
US5206366A (en) * 1992-08-26 1993-04-27 Pfizer Inc. Process for preparing aryl piperazinyl-heterocyclic compounds
US5312925A (en) 1992-09-01 1994-05-17 Pfizer Inc. Monohydrate of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2H-indol-2-one-hydrochloride
US5359068A (en) 1993-06-28 1994-10-25 Pfizer Inc. Processes and intermediates for the preparation of 5-[2-(4-(benzoisothiazol-3-yl)-piperazin-1-yl)ethyl]-6-chloro-1,3-dihydro-indol-2-one
CZ289216B6 (cs) 1996-05-07 2001-12-12 Pfizer Inc. Trihydrát methansulfonátu 5-(2-(4-(1,2-benzizothiazol-3-yl)-1-piperazinyl)ethyl)-6-chlor-1,3-dihydro-2H-indol-2-onu, farmaceutická kompozice a léčivo na jeho bázi

Also Published As

Publication number Publication date
EP0918772A1 (en) 1999-06-02
AU731267B2 (en) 2001-03-29
JP3494659B2 (ja) 2004-02-09
GT199700052A (es) 2001-08-29
CN1216991A (zh) 1999-05-19
CO4940466A1 (es) 2000-07-24
DK0918772T3 (da) 2005-01-10
MA24171A1 (fr) 1997-12-31
IS2080B (is) 2006-02-15
KR20000010824A (ko) 2000-02-25
OA10909A (en) 2001-10-26
NO312514B1 (no) 2002-05-21
PT918772E (pt) 2004-12-31
CZ349398A3 (cs) 1999-09-15
WO1997042191A1 (en) 1997-11-13
AU2174797A (en) 1997-11-26
BR9709889A (pt) 1999-08-10
DZ2222A1 (fr) 2002-12-03
HK1017892A1 (en) 1999-12-03
IL126591A0 (en) 1999-08-17
SK282837B6 (sk) 2002-12-03
CZ289215B6 (cs) 2001-12-12
SK150898A3 (en) 2000-02-14
CN1091769C (zh) 2002-10-02
EA001190B1 (ru) 2000-12-25
NO985194L (no) 1998-11-06
PL188330B1 (pl) 2005-01-31
TW491847B (en) 2002-06-21
DE69731094T2 (de) 2006-02-23
AP765A (en) 1999-09-17
CA2252898A1 (en) 1997-11-13
US6245765B1 (en) 2001-06-12
EP0918772B1 (en) 2004-10-06
PL329884A1 (en) 1999-04-12
JPH11509867A (ja) 1999-08-31
SI0918772T1 (en) 2005-02-28
KR100333215B1 (ko) 2002-06-20
TNSN97074A1 (fr) 2005-03-15
DE69731094D1 (de) 2004-11-11
NZ332218A (en) 2005-02-25
EG24076A (en) 2008-05-11
IS4874A (is) 1998-10-20
IL126591A (en) 2001-11-25
MY119997A (en) 2005-08-30
ATE278689T1 (de) 2004-10-15
ZA973876B (en) 1998-11-06
AP9700976A0 (en) 1997-07-31
ES2229342T3 (es) 2005-04-16
CA2252898C (en) 2003-04-08
EA199800912A1 (ru) 1999-04-29
NO985194D0 (no) 1998-11-06
ID16867A (id) 1997-11-20
HRP970236B1 (en) 2002-12-31
TR199802240T2 (cg-RX-API-DMAC7.html) 1999-02-22
HRP970236A2 (en) 1998-06-30
BG102892A (en) 1999-09-30
BG63544B1 (bg) 2002-04-30
UA46840C2 (uk) 2002-06-17

Similar Documents

Publication Publication Date Title
AR007004A1 (es) Sal de dihidrato de mesilato de 5-(2-(4-(1,2-benzoisotiazol-3-il)-1- piperazinil)etil)-6-cloro-1,3-dihidro-2h-indol-2-ona y composicionesfarmaceuticas que la contienen
ES2146300T3 (es) Utilizacion de composiciones antihelminticas para el tratamiento de infecciones causadas por anoplocephala perfoliata en equidos.
UY29182A1 (es) "derivados de bencenosulfonamidas sustituídas, composiciones que las contienen, procedimientos de preparación y aplicaciones"
ATE248837T1 (de) Chinuclidin-acrylamide
HN2009001145A (es) Compuestos y composiciones como inhibidores de proteina quinasa
AR089292A2 (es) Composicion herbicida a base de tien-3-il-sulfonilamino(tio)carbonil-triazolin(tio)onas substituidas, y metodos de aplicacion
DK0934937T3 (da) Azolderivater som superoxidradikalinhibitor
MX9602837A (es) Composiciones cosmeticas o farmaceuticas que contienen mangiferina o sus derivados.
DE69822668D1 (de) Heterozyklische ether- und thioether-verbindungen, verwendbar zur steuerung von chemischer synaptischer transmission
NO924696L (no) Fremgangsmaate for fremstilling av oksazolidinon- og tiazolidinon-derivater
AU2003259521A1 (en) Combination of a) n-{5-(4-(4-methyl-piperazino-methyl)-benzoylamido)-2-methylphenyl}-4-(3-pyridyl)-2-pyrimidine-amine and b) a histone deacetylase inhibitor for the treatment of leukemia
ES2421948T3 (es) Compuestos y composiciones para suministrar agentes activos
BR9606547A (pt) Novos derivados de pirimidona com atividade fungicida
ES2129485T3 (es) Derivados de acidos guanidinoalquil-1,1-bisfosfonicos, procedimiento para su preparacion y su utilizacion.
PT952974E (pt) Derivados bifenilicos substituidos por um radical aromatico ou heteroaromatico e composicoes farmaceuticas e cosmeticas que os contem
SV2003001213A (es) Agentes antidiabeticos ref. pcl8324
BR0109542A (pt) Derivados de imidazopirina alquilados
NO20050664L (no) 2,4 substituerte indoler og anvendelse derav som 5-HT6 modulatorer
BR0313684A (pt) Aparelho de maquiagem
SV2007002526A (es) Diarilsulfona sulfonamidas y el uso de las mismas ref. p1018
ES2180573T3 (es) Uso de derivados de indol como antagonistas de 5ht1.
ES2108482T3 (es) Productos solidos de cloruro de mepicuato y cloruro de clormecuato altamente concentrados.
ES2092868T3 (es) Utilizacion de derivados de la 4-tiorresorcina en unas composiciones cosmeticas o dermofarmaceuticas de accion despigmentante.
DE60309041D1 (de) Photochrome flüssigkristallverbindungen
SE8304408L (sv) Desoxiuridinderivat, forfaranden for deras framstellning och deras anvendning som lekemedel